CHOSA Oncology AB's abstract Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer accepted at 2023 ASCO Annual Meeting
CHOSA Oncology a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP[®] companion diagnostics for personalized cancer care, today announced that an abstract with the title ‘Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer’ has been accepted for a poster presentation at the world’s biggest and prestigious cancer conference American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023 in Chicago, USA.CEO Peter Buhl will present the data at the ASCO meeting taking